The Vanguard Group 13D and 13G filings for Intra-Cellular Therapies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:08 pm Purchase |
2023-12-29 | 13G | Intra-Cellular Therapies, Inc. ITCI |
The Vanguard Group | 9,094,302 9.450% |
775,053 (+9.32%) |
Filing |
| 2023-02-09 11:22 am Purchase |
2022-12-30 | 13G | Intra-Cellular Therapies, Inc. ITCI |
The Vanguard Group | 8,319,249 8.780% |
1,443,048 (+20.99%) |
Filing |
| 2022-02-10 08:17 am Purchase |
2021-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI |
The Vanguard Group | 6,876,201 8.440% |
394,857 (+6.09%) |
Filing |
| 2021-02-10 11:03 am Purchase |
2020-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI |
The Vanguard Group | 6,481,344 8.090% |
2,261,754 (+53.60%) |
Filing |